CI
GILD icon

CX Institutional’s Gilead Sciences GILD Stock Holding History

CX Institutional’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.01M Sell
26,913
-31,384
-54% -$4.4M 0.11% 187
2026
Q2 		$7.37M Sell
58,297
-76,191
-57% -$10M 0.21% 118
2026
Q1 		$18.7M Buy
134,488
+54,802
+69% +$7.67M 0.57% 37
2025
Q4 		$9.78M Buy
79,686
+5,774
+8% +$702K 0.29% 81
2025
Q3 		$8.2M Buy
73,912
+3,419
+5% +$389K 0.25% 94
2025
Q2 		$7.82M Buy
70,493
+1,846
+3% +$196K 0.27% 73
2025
Q1 		$7.69M Buy
68,647
+4,360
+7% +$450K 0.29% 80
2024
Q4 		$5.94M Buy
64,287
+3,300
+5% +$297K 0.24% 98
2024
Q3 		$5.11M Buy
60,987
+15,545
+34% +$1.19M 0.23% 121
2024
Q2 		$3.12M Sell
45,442
-2,446
-5% -$163K 0.15% 158
2024
Q1 		$3.51M Buy
47,888
+1,024
+2% +$78.7K 0.17% 146
2023
Q4 		$3.8M Buy
46,864
+7,680
+20% +$598K 0.2% 132
2023
Q3 		$2.94M Sell
39,184
-19,811
-34% -$1.52M 0.16% 167
2023
Q2 		$4.55M Buy
58,995
+2,411
+4% +$192K 0.24% 127
2023
Q1 		$4.71M Buy
56,584
+48,011
+560% +$3.98M 0.25% 111
2022
Q4 		$736K Buy
8,573
+889
+12% +$70.4K 0.04% 317
2022
Q3 		$474K Sell
7,684
-28,164
-79% -$1.78M 0.03% 341
2022
Q2 		$2.22M Buy
35,848
+3,207
+10% +$199K 0.17% 156
2022
Q1 		$1.94M Sell
32,641
-4,566
-12% -$292K 0.16% 157
2021
Q4 		$2.7M Sell
37,207
-14,837
-29% -$1.02M 0.21% 138
2021
Q3 		$3.63M Buy
52,044
+700
+1% +$49.2K 0.3% 92
2021
Q2 		$3.54M Buy
51,344
+3,254
+7% +$217K 0.29% 95
2021
Q1 		$3.11M Buy
48,090
+46,333
+2,637% +$2.99M 0.28% 95
2020
Q4 		$102K Buy
1,757
+747
+74% +$45.1K 0.01% 358
2020
Q3 		$64K Buy
1,010
+140
+16% +$9.71K 0.01% 358
2020
Q2 		$67K Buy
870
+57
+7% +$4.37K 0.01% 319
2020
Q1 		$61K Buy
813
+428
+111% +$29.6K 0.01% 301
2019
Q4 		$25K Sell
385
-477
-55% -$31.1K ﹤0.01% 326
2019
Q3 		$55K Sell
862
-258
-23% -$16.9K 0.01% 289
2019
Q2 		$76K Sell
1,120
-1,310
-54% -$86.2K 0.01% 293
2019
Q1 		$158K Buy
2,430
+2,373
+4,163% +$158K 0.03% 230
2018
Q4 		$4K Buy
+57
New +$3.98K ﹤0.01% 406

Other funds holding GILD

CIM
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.32B AUM 21.6% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
FFBTD
First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
SCA
Stokes Capital Advisors Greenwood, South Carolina $455M AUM 9.69% 1-Year Est. Return

CX Institutional's GILD Position: Q3 2026 in Review

CX Institutional reduced its Gilead Sciences (GILD) stake by 54% in Q3 2026, selling an estimated $4.4M and leaving 26,913 shares worth $4.01M. The position accounts for 0.11% of the portfolio, ranked #187.

CX Institutional first reported a position in GILD in Q4 2018 and has held it in 32 quarters since. The position peaked at $18.7M in Q1 2026. 119 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • CX Institutional held 26,913 shares of Gilead Sciences worth $4.01M as of Q3 2026.
  • CX Institutional sold 31,384 Gilead Sciences shares in Q3 2026, an estimated $4.4M.
  • Gilead Sciences made up 0.11% of CX Institutional's portfolio in Q3 2026, its #187 holding.
  • CX Institutional first reported a position in Gilead Sciences in Q4 2018 and has held it in 32 quarters since.
  • CX Institutional's Gilead Sciences position peaked at $18.7M in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.